Standard BioTools (LAB) Expected to Announce Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) will likely be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Standard BioTools to post earnings of ($0.03) per share and revenue of $43.03 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Standard BioTools Stock Down 0.7 %

NASDAQ:LAB opened at $1.40 on Wednesday. The stock’s fifty day moving average is $1.73 and its two-hundred day moving average is $1.82. Standard BioTools has a 52 week low of $1.17 and a 52 week high of $3.04. The stock has a market capitalization of $521.16 million, a price-to-earnings ratio of -1.97 and a beta of 1.57.

Wall Street Analyst Weigh In

Separately, TD Cowen decreased their price target on Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a research note on Thursday, October 31st.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.